In line with the observation of ING5 knockdown, UA was able to reverse sorafenib resistance in HCC cells by inhibiting ING5-ACC1/ACLY-LDs axis, suggesting that the combined with UA may effectively circumvent resistance to sorafenib in HCC therapy. Here, ACLY is linked to hepatocellular carcinoma.